#USA #Cambridge #Leap Therapeutics #Zcash #Cypherpunk Technologies

Cypherpunk Technologies Reports Third Quarter 2025 Results

Cypherpunk Technologies Inc., previously known as Leap Therapeutics Inc., has recently provided an update on its financial performance for the third quarter of 2025. With its headquarters in Cambridge, Massachusetts, the company is focused on developing innovative cancer therapies while also establishing a digital asset treasury strategy primarily centered around Zcash (ZEC).

Major Corporate Changes

On November 12, 2025, Cypherpunk Technologies announced its rebranding from Leap Therapeutics to reflect its new strategic priority of increasing investments in digital assets, particularly Zcash. The name change is accompanied by the company’s plan to begin trading on the Nasdaq Capital Market under the symbol “CYPH” starting November 13, 2025. This transition aligns with the company’s initiatives to advocate for privacy and liberty through digital assets. The cancer research and development arms will continue to operate under the newly named subsidiary, Leap Therapeutics, Inc.

Financial Highlights

In the month preceding this announcement, Cypherpunk successfully secured $58.88 million through a private placement led by Winklevoss Capital, facilitating its entry into the digital asset space. The company allocated $50 million specifically for acquiring Zcash, with significant purchases totaling 203,775.27 ZEC. The average price paid for ZEC was around $245.37, marking a substantial investment in what the company views as critical technology supporting user privacy in an increasingly digital world.

Douglas E. Onsi, the President and CEO, expressed optimism regarding recent developments: "This past month has been transformative for the Company, as we have closed a substantial funding round and begun acquiring ZEC."

Advancements in Cancer Treatment

In tandem with its digital initiatives, Cypherpunk Technologies is making notable strides in its pharmaceutical endeavors. The company recently presented promising results from its Phase 2 clinical trial involving sirexatamab, combined with bevacizumab and chemotherapy to treat advanced colorectal cancer. This trial was showcased at the European Society for Medical Oncology (ESMO) Congress, indicating the company’s commitment to advancing treatment options for patients with difficult-to-treat cancers.

The trial revealed statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) for patients treated with sirexatamab. For instance, patients exhibiting high levels of DKK1 showed an ORR of 38.0% compared to 23.7% for the control group. The median PFS also demonstrated favorable results, with a median duration of 9.03 months in the treatment group versus 7.06 months in the control cohort. Furthermore, the company is actively engaging regulatory bodies to explore potential pathways for commercializing sirexatamab in CRC treatment.

Financial Performance

For the third quarter of 2025, Cypherpunk reported a net loss of $3.3 million, a significant reduction from the $18.2 million loss recorded during the same period last year. This improvement was primarily due to decreased research and development expenditures, resulting from both strategic shifts and workforce reductions. The total research and development costs for Q3 2025 were reported at $1.2 million, down from $14.9 million year-over-year. General administrative expenses also fell from $2.9 million to $1.9 million during the same time frame.

As of September 30, 2025, the company's cash reserves stood at $9.7 million, preceding the completion of the recent private placement.

Looking Forward

Cypherpunk Technologies is focused on combining its pharmaceutical research with advancements in digital asset holdings. This dual strategy emphasizes not only the importance of cancer therapy innovations but also the growing relevance of cryptocurrency market engagement as a sustainable value creation model. The company looks forward to updating shareholders on the progress of its initiatives and developments set for the first quarter of 2026, particularly concerning the regulatory pathway for its cancer treatment and the expansion of its digital asset treasury strategy.

For more information, please visit Cypherpunk Technologies' official website or check the latest updates on public filings at the SEC’s EDGAR database.